Patterns of belatacept use and risk of post-transplant lymphoproliferative disorder in US kidney transplant recipients: An analysis of the Organ Procurement and Transplantation Network database.

<h4>Background</h4>Belatacept is approved for the prophylaxis of organ rejection in Epstein-Barr virus (EBV)-seropositive kidney transplant recipients and is associated with a risk of post-transplant lymphoproliferative disorder (PTLD).<h4>Methods</h4>Data from the Organ Proc...

Full description

Saved in:
Bibliographic Details
Main Authors: Wida S Cherikh, Tzuyung Douglas Kou, Julia Foutz, Timothy J Baker, Andres Gomez-Caminero
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0311935
Tags: Add Tag
No Tags, Be the first to tag this record!